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Summary Secondary ivermectin prophylaxis for strongyloidiasis in two patients with human
T-cell lymphotropic virus type 1 (HTLV-1)-associatedmalignancies and fully treated complicated
strongyloidiasis is described. Treatment was well tolerated and neither patient developed
further manifestations of hyperinfection. As treatment failure for complicated strongyloidiasis
has been documented in severely immunosuppressed patients, secondary prophylaxis may be
indicated.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Vigilance for Strongyloides stercoralis infection is important,
even in non-endemic regions. Although endemic to tropical
and subtropical regions, this intestinal helminth is increas-
ingly common in other areas, due to the popularity of travel
to and immigration from endemic areas. Chronic infection is
often asymptomatic or accompanied by vague gastrointest-
inal symptoms, and may remain undetected for up to six
decades.1 Although chronic strongyloidiasis frequently car-
ries low morbidity, it does have the potential to develop into* Corresponding author. Tel.: +1 613 737 8184; fax: +1 613 737 8164.
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(A.E. McCarthy).
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doi:10.1016/j.ijid.2009.02.009one of the complicated forms of infection — hyperinfection
and disseminated infection — which carry a mortality rate of
up to 70%, even with appropriate therapy.2—4
Immunosuppression, most notably human T-cell lympho-
tropic virus type 1 (HTLV-1) infection and chronic corticos-
teroids, are the greatest risk factors for complicated
strongyloidiasis in the infected individual. Therefore,
empiric therapy is recommended prior to at-risk patients
undergoing chemotherapy, chronic corticosteroid use, or
other severe forms of immunosuppression such as organ
transplant.5,6 However, treatment failures have been
reported, and there are case reports of patients developing
complicated strongyloidiasis even after a recommended dose
of prophylactic antihelminthics.7 This is not surprising when
considering the autoinfective nature of the parasite. There-
fore, it may be more appropriate to view strongyloidiasis as aPublished by Elsevier Ltd. All rights reserved.
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completely eradicated. Continued prophylactic/empiric
treatment in immunosuppressed patients with prior strongy-
loidiasis or at high risk of infection should be considered. The
current literature is limited in this area, although some
authors state that ongoing prophylactic treatment may be
beneficial for patients with a history of previously treated S.
stercoralis infection and risk factors for hyperinfection/dis-
semination. There is, however, no literature to date report-
ing ivermectin use in this way. This paper reviews two cases of
patients with HTLV-1-associated malignancies and strongy-
loides infection who were maintained on long-term inter-
mittent ivermectin following complicated strongyloidiasis.
Case reports
In the first case, a 26-year-old female immigrant from Haiti,
seropositive for HTLV-1 and undergoing active chemotherapy
for T-cell leukemia, presented to The Ottawa Hospital with
nausea, vomiting, diarrhea, and syndrome of inappropriate
antidiuretic hormone (SIADH). Her course was complicated
by Gram-negative bacterial meningitis, polymicrobial gram-
negative bacteremia, endocarditis, and a massive upper
gastrointestinal bleed. Pathology of gastric and duodenal
esophagogastroduodenoscopy (EGD) samples revealed the
etiology as S. stercoralis infection, 21 days following admis-
sion. Thiabendazole was initially administered, but discon-
tinued after seven days due to adverse effects. Clinical
remission was achieved with two days of ivermectin therapy
(200 mg/kg/day), followed by a third dose taken 10 days
later. Remission was confirmed with three repeated negative
stool samples, and an EGD biopsy taken 17 days later revealed
no living parasites, granulomas from dead parasites, and
ulcers in various stages of activity and repair. The patient
recovered from her acute illness and was discharged from
hospital with the plan of ongoing intermittent ivermectin
prophylaxis (200 mg/kg for two days) every four to six weeks.
She received two prophylactic doses with no reported
adverse effects or relapse of strongyloidiasis. She succumbed
to the leukemia a couple of weeks later.
In the second case, a previously healthy 41-year-old male
immigrant from Togo presented to The Ottawa Hospital with
post-prandial epigastric pain and diarrhea. On work-up,
HTLV-1 serology was positive, and EGD biopsy revealed S.
stercoralis infection, HTLV-1-associated T-cell non-Hodgkin’s
lymphoma, Helicobacter pylori, giardiasis, and Candida eso-
phagitis. Chronic strongyloidiasis was treated with thiaben-
dazole (1.5 g twice a day for two days). Stool samples to
determine clearance of infection were sent 10 days post-
treatment, and chemotherapy was initiated prior to receiv-
ing these results. The post-treatment stool samples were
positive for larvae, and one dose of ivermectin at 200 mg/kg
was administered. Eight days later, the patient presented
with a high fever and pneumonia, clinically suspected to be
strongyloides hyperinfection. Symptoms resolved with 12
days of thiabendazole and broad-spectrum antibiotics, and
repeated stool samples were negative. Over the next nine
months, the patient underwent several more cycles of che-
motherapy. Although he had several further admissions for
febrile neutropenia, S. stercoralis was not identified on
repeat stool samples, and no clear source of infection was
identified. Each of these episodes resolved with a combina-tion of ivermectin and broad-spectrum antibiotics. Due to
risk factors for strongyloides hyperinfection, he was placed
on prophylactic ivermectin (200 mg/day) for two days every
four to six weeks. Nine months after initial presentation, the
patient succumbed to a gram-negative bacteremia (Escher-
ichia coli). It is not known if this may have been secondary to
refractory strongyloidiasis or his immunocompromised state,
as no autopsy was performed. However, since the gastroin-
testinal lymphoma and chemotherapy predisposed him to
gram-negative bacteremia, and there were no other con-
current gram-negative infections, it is presumed the bacter-
emia was not due to disseminated strongyloidiasis.
Discussion
These two cases describe patients with HTLV-1 related hema-
tologic malignancies, who had endemic risk factors for stron-
gyloidiasis and developed the complicated form of the
infection. This is compatible with the medical literature,
which documents not only an increased prevalence of stron-
gyloidiasis in HTLV-1-positive patients,8 but also an increased
incidence of complicated strongyloidiasis. In one Peruvian
study comparing disease patterns of strongyloidiasis, HTLV-1
was identified in 85.7% of patients with hyperinfection,
compared to 10% of patients with intestinal strongyloidiasis
and 4.7% of patients with negative stool samples for stron-
gyloides.9 Additionally, strongyloides is more refractory to
therapy in HTLV-1-positive patients.9 In a study by Satoh
et al., remission was achieved in only 40.6% of HTLV-1-
positive patients receiving albendazole, compared to
66.0% in HTLV-1-negative patients.10 Data on successful
remission with ivermectin in HTLV-1-positive patients is lim-
ited to case reports.11,12
Both patients described here had endemic risk factors for
strongyloidiasis. The patient in case 1 did not receive screen-
ing or prophylactic treatment prior to the initiation of che-
motherapy. The patient in case 2, who was diagnosed with
HTLV-1 and intestinal strongyloidiasis concurrently, did
receive appropriate treatment for infection immediately,
prior to initiation of chemotherapy. Unfortunately, lym-
phoma chemotherapy was initiated prior to documented
clearance of infection, as the strongyloidiasis was refractory
to the initial course of thiabendazole. He subsequently
received one dose of ivermectin. Although he was thought
to have cleared the infection, symptoms likely due to hyper-
infection occurred eight days later. Of note, thiabendazole,
which was the first-line therapy at the time of his presenta-
tion, is currently not recommended due to problems with
supply and due to the availability of ivermectin, which has a
better efficacy and lower adverse effect profile.
Screening for strongyloidiasis is recommended in HTLV-1-
positive patients, due to its increased prevalence and risk of
the complicated form of infection.6 Patients with epidemio-
logic risk factors for strongyloidiasis should also be given a pre-
emptive/prophylactic anthelmintic to treat a possible occult
infection. However, such treatment is not always successful.
The refractoriness to treatment of S. stercoralis can be
explained by its autoinfective nature. As a single rhabditiform
larva can replicate, every parasite must be eradicated to
prevent ongoing replication. To make matters worse, com-
plete eradication is impossible to determine. Stool examina-
tion, considered thegold standard for diagnosis, is specific, but
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ally, it is operator-dependent, and has a sensitivity of only 15—
60% for the most commonly used methods13 (variation depen-
dent on number of samples and method of preparation used).
A potentially promising method for determining response
to treatment is following sequential serology, most com-
monly the ELISA. Antibody titers decrease after therapy,
and the ratio of pre- and post-treatment antibody levels,
using a cut-off of <0.6, can be used to document response.14
Although this method has been useful to determine response
to therapy in some studies,15,16 it is unclear if serology can
determine complete eradication of strongyloides. For this
reason and due to the potentially devastating consequences
of complicated infection, it may be appropriate to stray from
the traditional view that strongyloidiasis can be eradicated,
and instead consider it a chronic infection that can be
suppressed, but not completely eradicated.
As a result, it may be appropriate to give intermittent
prophylactic therapy to patients with HTLV-1 infection, par-
ticularly those with a history of complicated strongyloidiasis.
Even stronger consideration must be given to those under-
going chemotherapy. The current drug of choice for therapy
is ivermectin, with albendazole as the alternative, since
ivermectin has few adverse effects and a better success rate
than albendazole in treating strongyloides.16—18 Ivermectin,
at a dose of 200 mg/kg for one to two days every four to six
weeks was the anthelmintic used in our cases, and was
tolerated well. Neither patient developed further manifes-
tations of complicated strongyloidiasis.
In conclusion, complicated strongyloidiasis is a serious and
frequently fatal infection. Both HTLV-1 infection and che-
motherapy predispose previously infected patients to hyper-
infection or disseminated strongyloidiasis. Initial screening
and prophylactic treatment is necessary in patients with
epidemiologic risks for strongyloidiasis. However, complete
eradication is impossible to determine by current methods.
Therefore it may be appropriate to treat these patients,
especially those with associated malignancies or undergoing
chemotherapy, with ongoing intermittent ivermectin ther-
apy. Further study in this area will be needed to determine
that this is advantageous.
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